Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Average Target Price of $32.43 According to Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus recommendation of “Hold” from the fifteen brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $32.43.

HIMS has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Bank of America lifted their target price on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Barclays decreased their price target on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Morgan Stanley increased their price target on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Finally, TD Cowen increased their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 3,461 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $29.06, for a total value of $100,576.66. Following the transaction, the insider owned 297,348 shares of the company’s stock, valued at $8,640,932.88. This represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the completion of the transaction, the chief operating officer directly owned 456,660 shares in the company, valued at $12,964,577.40. The trade was a 2.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 130,443 shares of company stock worth $3,731,426. Company insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Hims & Hers Health during the second quarter worth approximately $46,220,000. Bienville Capital Management LLC purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $27,242,000. Principal Financial Group Inc. lifted its position in shares of Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after buying an additional 632,282 shares during the last quarter. Finally, Southpoint Capital Advisors LP purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth approximately $10,380,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers has asked a federal judge to dismiss the Federal Trade Commission’s complaint concerning subscription practices and privacy. A successful dismissal could reduce potential legal costs, penalties and reputational damage. Hims & Hers seeks dismissal of FTC lawsuit
• Positive Sentiment: The company added testosterone injections and an FDA-approved pill, expanding its men’s-health offerings and potentially increasing customer acquisition and revenue opportunities. Hims & Hers adds testosterone injections and an FDA-approved pill
• Neutral Sentiment: Investors are looking ahead to the company’s next major update, with November 9 expected to provide additional information on the performance of its men’s-health launch and business outlook. Hims & Hers stock and November 9 outlook
• Negative Sentiment: Multiple law firms are promoting a securities class action against Hims & Hers and certain executives. The case alleges investors were harmed by disclosures related to the FTC’s complaint, which accuses the company of serious business misconduct involving subscriptions and privacy. The allegations have not been proven, but the litigation adds legal, financial and reputational uncertainty. Hims & Hers facing securities class action
• Negative Sentiment: Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have been reminded that November 2, 2026 is the lead-plaintiff deadline. The unusually high volume of law-firm notices reinforces the market’s focus on regulatory exposure, even though the announcements themselves do not represent new financial penalties. Hims securities class action deadline alert

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $27.70 on Thursday. The firm has a 50 day simple moving average of $29.12 and a 200-day simple moving average of $29.05. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $50.99. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The stock has a market cap of $6.46 billion, a price-to-earnings ratio of -43.96 and a beta of 2.44.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm’s quarterly revenue was up 38.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.17 EPS. On average, analysts expect that Hims & Hers Health will post -0.16 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.